Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly
After Novo Nordisk and AstraZeneca, Novartis is the third big pharma to suffer a major cardiovascular outcomes trial failure in the past two months. The Swiss pharma reported Friday that pelacarsen was no better than ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.